Based on the Voyager Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Voyager Therapeutics Inc is USD 15.60 over the next 12 months. Voyager Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Voyager Therapeutics Inc is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Voyager Therapeutics Inc’s stock price was USD 6.57. Voyager Therapeutics Inc’s stock price has changed by +15.87% over the past week, -6.14% over the past month and -13.67% over the last year.
No recent analyst target price found for Voyager Therapeutics Inc
No recent average analyst rating found for Voyager Therapeutics Inc
Company Overview Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Read Less
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide...Read More
Frequently Asked Questions About Voyager Therapeutics Inc (VYGR) Stock
Based on ratings from 4 analysts Voyager Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on VYGR's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for VYGR is USD 15.60 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 7.
VYGR stock's Price/Earning ratio is 8.12.
Our analysis grades VYGR stock's Price / Earning ratio at F. This means that VYGR stock's Price/Earning ratio is above 53% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VYGR may be a overvalued for its sector.
The last closing price of VYGR's stock was USD 6.57.
The most recent market capitalization for VYGR is USD 0.29B.
Based on targets from 4 analysts, the average taret price for VYGR is projected at USD 15.60 over the next 12 months.
This means that VYGR's stock price may go up by +137.44% over the next 12 months.
We can't find any ETFs which contains Voyager Therapeutics Inc's stock.
As per our most recent records Voyager Therapeutics Inc has 162 Employees.
Voyager Therapeutics Inc's registered address is 75 Hayden Avenue, Lexington, MA, United States, 02421.
You can get more information about it from Voyager Therapeutics Inc's website at https://www.voyagertherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Voyager Therapeutics Inc (VYGR) Stock
Based on ratings from 4 analysts Voyager Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on VYGR's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for VYGR is USD 15.60 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 7.
VYGR stock's Price/Earning ratio is 8.12.
Our analysis grades VYGR stock's Price / Earning ratio at F. This means that VYGR stock's Price/Earning ratio is above 53% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VYGR may be a overvalued for its sector.
The last closing price of VYGR's stock was USD 6.57.
The most recent market capitalization for VYGR is USD 0.29B.
Based on targets from 4 analysts, the average taret price for VYGR is projected at USD 15.60 over the next 12 months.
This means that VYGR's stock price may go up by +137.44% over the next 12 months.
We can't find any ETFs which contains Voyager Therapeutics Inc's stock.
As per our most recent records Voyager Therapeutics Inc has 162 Employees.
Voyager Therapeutics Inc's registered address is 75 Hayden Avenue, Lexington, MA, United States, 02421.
You can get more information about it from Voyager Therapeutics Inc's website at https://www.voyagertherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VYGR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
